Connect with us

Business

From early flop to Hollywood heavyweight, Skydance eyes Warner Bros takeover after 20-year rise – The Times of India

Published

on

From early flop to Hollywood heavyweight, Skydance eyes Warner Bros takeover after 20-year rise – The Times of India


Two decades after debuting with a box office failure that drew harsh reviews, Skydance Productions is now poised to become one of the most powerful forces in global entertainment, with a proposed takeover of Warner Bros. Discovery marking the latest chapter in its dramatic rise, according to news agency AP report.Founded in 2006 by David Ellison, son of Oracle co-founder Larry Ellison, the studio began as a relatively obscure entrant in Hollywood. Its first film, Flyboys, a World War I drama starring Ellison himself, failed commercially and critically, prompting early doubts about the company’s future.Yet the studio steadily built momentum through partnerships, strategic financing and franchise-driven successes. Today, following its merger with Paramount and a fresh bid to acquire Warner Bros. Discovery, Skydance stands on the verge of transforming into a media powerhouse spanning film, television, streaming and news assets.“It’s only a surprise to those who haven’t been paying attention to the long game,” said Walter Nicoletti, founder of film production company Voce Spettacolo. “This is a sort of a silent takeover. Skydance didn’t start as a predator. It started as an essential partner.”

From outsider to industry player

When Ellison launched Skydance at age 23, the company barely registered in Hollywood’s competitive landscape. Early criticism of Flyboys was scathing, with reviewers calling it “cloyingly formulaic” and an “inflated wannabe epic.”Despite setbacks, Ellison continued investing in large-scale productions and partnerships with major studios and platforms including Paramount, Netflix and Apple. Over time, Skydance produced a string of commercially successful films and series, culminating in the billion-dollar hit Top Gun: Maverick in 2022 starring Tom Cruise.Jason Squire, a former studio executive and emeritus professor at the University of Southern California, said Ellison’s rise reflected both persistence and financial backing.“One of the traditions of entering the movie business is serious wealth, or access to serious wealth,” Squire said, AP quoted. “But once you get a foothold, you have to demonstrate that wealth — by buying things, acquiring projects… They became a player.”He added, “He became a member at the table when these partnerships and the infusion of dollars really set him up on a really strong trajectory. It’s quite amazing.”

Expansion through mergers and deals

Rather than being acquired by a larger studio, Skydance ultimately became the acquirer. After years of collaboration, it merged with Paramount last year, gaining control of networks including MTV, Comedy Central, Nickelodeon and CBS.Since then, Ellison has expanded aggressively, securing agreements ranging from streaming rights for Ultimate Fighting Championship to partnerships with creators of the hit series Stranger Things.Netflix had also been viewed as a potential buyer of Warner Bros. Discovery, but Skydance ultimately emerged as the winning bidder after the streaming giant withdrew its offer. Regulatory approval remains the final hurdle.Tre Lovell, a Los Angeles media lawyer, described the company’s ascent as unprecedented. “This was absolutely a meteoric rise. Two decades from its formation to its current position to become one of the most powerful media companies in the world is nothing less than incredible,” he said.

A reshaped media landscape

If the Warner deal is finalised, Ellison would oversee an expansive portfolio including HBO, HGTV, Food Network and CNN, significantly expanding Skydance’s footprint across entertainment and news.The move also highlights shifting industry dynamics, with consolidation raising concerns among some executives about reduced competition. Squire said he was “no fan” of the takeover despite acknowledging Skydance’s remarkable trajectory.Warner Bros. enters the deal from a position of creative strength, having secured 30 Oscar nominations and a 21% domestic box-office share in 2025, compared with Paramount’s 6%.For Ellison, the transformation marks a striking reversal from the early days when the failure of Flyboys reportedly left him hospitalised with atrial fibrillation. Two decades later, the studio once dismissed as a vanity project now stands at the centre of Hollywood’s biggest power shift.“Hollywood has seen David-versus-Goliath moments before,” said Vikrant Mathur, co-founder of streaming company Future Today.



Source link

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Business

Why Spotify has no button to filter out AI music

Published

on

Why Spotify has no button to filter out AI music



Music streamer Deezer allows users to filter out AI music, so why does Spotify not offer the same?



Source link

Continue Reading

Business

‘I had £20,000 stolen and had to fight a 13-month fraud reporting rule to get it back’

Published

on

‘I had £20,000 stolen and had to fight a 13-month fraud reporting rule to get it back’



Sarah has now got her money back but there are calls to reform the deadline for reporting scams to banks.



Source link

Continue Reading

Business

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

Published

on

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial


Intellia Therapeutics, building exterior and company sign, Cambridge, Massachusetts, USA.

Spencer Grant | Universal Images Group | Getty Images

Intellia Therapeutics said its Crispr-based treatment for a rare swelling condition met its goals in a late-stage trial, marking a milestone for the field of gene editing and putting the company on track to seek approval from the U.S. Food and Drug Administration.

The company’s treatment uses Nobel Prize-winning technology Crispr to edit DNA and turn off the gene that controls production of a peptide that’s overactive in people with hereditary angioedema, causing them to experience potentially life-threatening swelling attacks. Intellia’s treatment is administered once through an hourslong infusion, making the edits directly in the liver.

Intellia said the one-time treatment reduced attacks by 87% compared with a placebo, meeting the study’s main goal. Six months after treatment, 62% of patients were free from attacks and weren’t using other therapies, Intellia said.

The company described the safety and tolerability of the treatment as “favorable,” reporting the most common side effects were infusion-related reactions, headaches and fatigue. Analysts were closely watching safety in the trial since a patient in a separate trial of a different treatment from Intellia died. That patient developed a liver injury and ultimately died from septic shock following an ulcer, according to the company.

“When you think about where we started with Crispr, just 12 years ago with some of the fundamental insights, I think there was a lot of talk about what might be possible, and we’ve had reports along the way in terms of milestones, but this is the first Phase 3 data in any indication with in vivo Crispr where you’re actually changing a gene that causes disease,” said Intellia CEO John Leonard.

The only FDA-approved Crispr-based medicine comes from Vertex Pharmaceuticals. Called Casgevy, the gene editing is done outside the body, or ex vivo. The process requires collecting a person’s blood cells, making the edits outside the body, then reinfusing them back into a patient. Intellia’s treatment, meanwhile, makes the edits inside the body, or in vivo.

Intellia said it has started a rolling application with the FDA and plans to complete the filing in the second half of this year. The company expects to launch the treatment in the U.S. in the first half of next year, if it’s approved.

If approved, Intellia’s treatment, lonvoguran ziclumeran, will compete with about a dozen other chronic drugs for HAE. Despite the allure of a one-time treatment, genetic medicines haven’t always been a commercial successes. BioMarin withdrew its gene therapy for Hemophilia A because of weak sales, for example.

Leonard said there are important differences between the two, like the fact that BioMarin’s therapy faced questions about how long the effects would last. In contrast, he said Intellia hasn’t seen a single case in almost six years where the effects diminished over time.

Despite the results, he’s reluctant to call Intellia’s treatment a functional cure.

“I think this is a tipping point for the disease and tipping point for Crispr-based in vivo therapy where you can make a change [and] it’s permanent,” Leonard said. “And, as far as we can tell, we don’t have a single patient in this program or other program where there’s been any waning of the effect of what we did to the gene or the effect of what we’ve seen with the clinical aspects of the disease itself. So it’s pretty exciting.”

Clarification: This story has been updated to clarify that a patient in a separate trial of a different treatment from Intellia developed acute liver injury and ultimately died from septic shock following an ulcer.

Choose CNBC as your preferred source on Google and never miss a moment from the most trusted name in business news.



Source link

Continue Reading

Trending